This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

The PROfound trial: efficacy and safety data

Length: 06:28

On 26 January 2021, AstraZeneca and MSD organised a webcast on challenging the treatment paradigm for mCRPC with precision medicine in UK practice. You can watch a recording of this webcast with Dr Joaquin Mateo presenting the PROfound trial efficacy and safety data.

Dr Joaquin Mateo presents the PROfound trial efficacy and safety data. PROfound is a phase 3 randomised, open-label, phase 3 trial evaluating the PARP inhibitor olaparib (LYNPARZA™) in men with metastatic castration-resistant prostate cancer, who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone).1

More information about LYNPARZA™ (olaparib) in Prostate Cancer:

LYNPARZA is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.1

References

  1. LYNPARZA (tablets) Summary of Product Characteristics.

Supporting documentation

100 mg and 150 mg film coated tablets – Great Britain
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

100 mg and 150 mg film coated tablets – Northern Ireland
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-28506 | Date of Preparation: June 2021